Back to top

Analyst Blog

The European Commission (EC) has recently granted marketing authorization for Dendreon Corporation’s (DNDN - Analyst Report) Provenge. The drug is approved in the EU for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in adults. Chemotherapy is not yet clinically indicated for these patients.

The EU approval of Provenge does not come as a surprise as, in Jun 2013, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) provided a positive opinion on the approval of the drug. Dendreon also received a favorable opinion from the EMA’s Committee for Advanced Therapy (CAT) on its marketing application for Provenge.

Provenge’s approval in the EU was based on positive results from the phase III IMPACT (n=737) study in patients suffering from prostate cancer. Results from the study revealed an improvement in overall survival in patients treated with Provenge compared to those in the placebo arm.

Provenge, Dendreon’s sole marketed product, has been approved in the U.S. for treating advanced prostate cancer since May 2010. We remind investors that the drug performed disappointingly in the second quarter of 2013 with sales declining 8.4% to $73.3 million. The sharp decline in Provenge sales was primarily due to the entry of Johnson & Johnson’s (JNJ - Analyst Report) Zytiga in the prostate cancer market in Dec 2012.
Meanwhile, management stated in its second quarter 2013 conference call that Provenge sales will not be able to beat the 2012 sales figure of $325.3 million. Though encouraged by the EU approval, we remain concerned about the decreasing trend of Provenge sales. We are also concerned about Dendreon’s high dependence on Provenge for growth.

Dendreon carries a Zacks Rank #3 (Hold). Meanwhile companies such as Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB - Analyst Report) look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%